Certolizumab Pegol

A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.

Also Known As:

Networked: 531 relevant articles (103 outcomes, 156 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Sandborn, William J: 25 articles (01/2022 - 02/2003)
2.	van der Heijde, Désirée: 23 articles (01/2022 - 07/2012)
3.	Schreiber, Stefan: 17 articles (01/2021 - 09/2005)
4.	Hoepken, Bengt: 14 articles (09/2022 - 01/2017)
5.	Landewé, Robert: 13 articles (01/2022 - 11/2008)
6.	Bauer, Lars: 12 articles (09/2022 - 01/2017)
7.	Emery, Paul: 12 articles (01/2020 - 11/2008)
8.	Watanabe, Akira: 11 articles (07/2022 - 07/2014)
9.	Combe, Bernard: 11 articles (07/2021 - 11/2008)
10.	Curtis, Jeffrey R: 11 articles (01/2021 - 06/2011)

Related Diseases

1.	Crohn Disease (Crohn's Disease) 10/01/2014 - "Certolizumab pegol was well tolerated in the long-term treatment of Crohn's disease, with sustained remission in some patients continuing in the study for up to 7 years. " 01/01/2022 - "Certolizumab pegol (CZP) is effective for moderately to severely active Crohn's disease (CD). " 08/01/2013 - "Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn's Disease? " 10/01/2014 - "Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study." 07/01/2010 - "We sought to analyze the efficacy (response and remission) and safety data from the PRECiSE 2 trial of certolizumab pegol according to duration of Crohn's disease since diagnosis at baseline. "
2.	Rheumatoid Arthritis 01/01/2019 - "The aim of this study, based on a post hoc analysis of the data set used in the RAPID 1 trial, focuses on the associations between metacarpal bone mineral density, as estimated by digital X-ray radiogrammetry (DXR), and clinical remission as well as ACR70-Response in rheumatoid arthritis (RA) patients treated with certolizumab pegol (CZP). " 06/01/2011 - "Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial." 10/01/2002 - "Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial." 01/13/2011 - "The construct validity and reliability of the SIAQ were tested in patients with rheumatoid arthritis who volunteered to inject certolizumab pegol using a standard syringe during an open-label multinational extension trial of the long-term safety and efficacy of this drug. " 01/01/2020 - "Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis."
3.	Necrosis 01/01/2018 - "This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregnant women to their infants. " 12/01/2022 - "To evaluate the number and nature of reported congenital malformations (CMs) after intrauterine exposure to non-tumour necrosis factor inhibitor biologics (non-TNFi biologics) compared to certolizumab pegol (CZP). " 01/01/2022 - "Certolizumab pegol (CZP) is a biological agent that regulates the impaired immune response by controlling tumour necrosis factor-α (TNFα). " 04/01/2014 - "Certolizumab pegol is the only PEGylated anti-tumour necrosis factor (TNF)-α agent. " 07/01/2012 - "Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent. "
4.	Axial Spondyloarthritis 01/01/2023 - "RAPID-axSpA (NCT01087762) was a 204-week phase III trial evaluating the safety and efficacy of certolizumab pegol (CZP) in adult patients with active axSpA. " 06/01/2014 - "In two ongoing, well-designed studies, data at 12 and 24 weeks showed that treatment with certolizumab pegol (200 mg every 2 weeks or 400 mg every 4 weeks) was effective in improving the clinical signs and symptoms of disease, health-related quality of life and productivity in patients with axSpA (the RAPID-axSpA study) or PsA (the RAPID-PsA study), with the improvements maintained during longer-term (48 weeks) treatment. " 09/01/2020 - "Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE." 01/01/2022 - "In RAPID-axSpA (NCT01087762), a 4-year, phase 3 randomized trial, participants were randomized to certolizumab pegol (CZP; 400 mg loading dose at Weeks 0/2/4 then 200/400 mg every 2/4 weeks) or placebo (PBO) at baseline; PBO-randomized participants switched to CZP at Week 16/24 (denoted PBO-randomized/CZP). " 01/01/2022 - "Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study."
5.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2021 - "However, certolizumab pegol is only approved for plaque psoriasis in dermatology; it is likely to be a promising effective agent for HS, especially in challenging cases." 01/01/2021 - "Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)." 01/01/2021 - "Long-term efficacy of certolizumab pegol for psoriasis." 06/01/2023 - "Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)." 01/01/2023 - "Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)."

Related Drugs and Biologics

1.	Adalimumab (Humira)
2.	Infliximab (Remicade)
3.	Methotrexate (Mexate)
4.	golimumab
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	Etanercept (Enbrel)
7.	Antirheumatic Agents (DMARD)
8.	Tumor Necrosis Factor Inhibitors
9.	Immunoglobulin Fab Fragments
10.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Tapering
3.	Biological Therapy
4.	Knee Replacement Arthroplasty (Total Knee Replacement)
5.	Renal Dialysis (Hemodialysis)